Texas Permanent School Fund Corp Invests $2.57 Million in Hims & Hers Health, Inc. $HIMS

Texas Permanent School Fund Corp acquired a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) in the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 51,532 shares of the company’s stock, valued at approximately $2,569,000.

Other large investors also recently added to or reduced their stakes in the company. Virtus Advisers LLC purchased a new position in shares of Hims & Hers Health during the second quarter worth $26,000. Quaker Wealth Management LLC acquired a new position in Hims & Hers Health during the 2nd quarter worth about $29,000. Bessemer Group Inc. boosted its holdings in Hims & Hers Health by 105.8% during the 2nd quarter. Bessemer Group Inc. now owns 607 shares of the company’s stock valued at $30,000 after acquiring an additional 312 shares during the period. Geneos Wealth Management Inc. acquired a new position in Hims & Hers Health in the 1st quarter valued at about $30,000. Finally, Skandinaviska Enskilda Banken AB publ increased its stake in Hims & Hers Health by 408.2% during the second quarter. Skandinaviska Enskilda Banken AB publ now owns 747 shares of the company’s stock worth $37,000 after purchasing an additional 600 shares during the period. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. Barclays initiated coverage on shares of Hims & Hers Health in a report on Monday, December 8th. They issued an “overweight” rating and a $48.00 price objective for the company. Leerink Partnrs upgraded shares of Hims & Hers Health from a “hold” rating to a “strong-buy” rating in a research note on Thursday, December 4th. UBS Group set a $32.00 price objective on Hims & Hers Health in a research note on Tuesday, November 4th. Weiss Ratings reiterated a “hold (c)” rating on shares of Hims & Hers Health in a report on Monday, December 15th. Finally, Canaccord Genuity Group restated a “buy” rating and set a $68.00 price target on shares of Hims & Hers Health in a report on Friday, September 12th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, ten have issued a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat, Hims & Hers Health currently has a consensus rating of “Hold” and an average target price of $45.50.

Hims & Hers Health Price Performance

Hims & Hers Health stock opened at $35.49 on Friday. The company has a current ratio of 1.88, a quick ratio of 1.64 and a debt-to-equity ratio of 1.67. The company has a fifty day simple moving average of $41.85 and a 200-day simple moving average of $48.49. The stock has a market cap of $8.08 billion, a P/E ratio of 65.72, a price-to-earnings-growth ratio of 7.03 and a beta of 2.41. Hims & Hers Health, Inc. has a 12-month low of $23.97 and a 12-month high of $72.98.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, November 3rd. The company reported $0.06 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.03). Hims & Hers Health had a return on equity of 24.67% and a net margin of 6.05%.The business had revenue of $598.98 million for the quarter, compared to analyst estimates of $578.99 million. During the same period last year, the business posted $0.32 EPS. Hims & Hers Health’s revenue was up 49.2% on a year-over-year basis. Equities analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Hims & Hers Health declared that its Board of Directors has initiated a stock repurchase plan on Monday, November 17th that permits the company to repurchase $250.00 million in outstanding shares. This repurchase authorization permits the company to repurchase up to 3% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s board believes its stock is undervalued.

Insider Buying and Selling

In related news, insider Deborah M. Autor sold 7,054 shares of the company’s stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total value of $258,952.34. Following the completion of the sale, the insider owned 6,175 shares in the company, valued at $226,684.25. This represents a 53.32% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Garcia Andrea G. Perez sold 2,500 shares of Hims & Hers Health stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $39.17, for a total transaction of $97,925.00. Following the completion of the transaction, the director owned 80,166 shares in the company, valued at approximately $3,140,102.22. This represents a 3.02% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 233,429 shares of company stock valued at $11,769,372 in the last 90 days. Company insiders own 13.71% of the company’s stock.

Hims & Hers Health News Roundup

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Hims & Hers announced a roughly US$200 million investment to expand its New Albany, Ohio operations — a move reporters say could quietly redefine its core strategy by expanding fulfillment/operational capacity and creating ~400 jobs. Investors often view large, strategic capacity investments as potential drivers of revenue growth and margin improvement over time. Is Hims & Hers Health’s US$200 Million Ohio Bet Quietly Redefining Its Core Strategy (HIMS)?
• Positive Sentiment: The company has an active share-repurchase program — the board authorized up to $250M (about 3% of shares) — which can support the stock by reducing float and signaling management confidence in valuation. Hims, Block, and NRG Just Launched Huge Stock Buybacks
• Neutral Sentiment: Analyst / media cautions: a Zacks piece flagged HIMS among high-growth medtech/telehealth names that could slow in 2026 — a reminder that momentum names carry execution and multiple-compression risk. 3 Skyrocketing MedTech Stocks That Might Lose Steam in 2026
• Neutral Sentiment: Large institutional ownership remains significant (e.g., Farallon, Invesco increased stakes), which can stabilize share demand but also concentrate price action; this is background context for liquidity and investor flows. HIMS company page (MarketBeat)
• Negative Sentiment: Several insiders sold shares on Dec. 17 (including Deborah Autor, Irene Becklund, Patrick Carroll and COO Michael Chi) — transactions together total roughly $1.4M+ and include large percentage reductions for some insiders. Concentrated insider selling, particularly from senior executives, can spook momentum traders and suggests some tax/liquidity-driven exits or portfolio trimming. Hims & Hers Health (NYSE:HIMS) Insider Sells $258,952.34 in Stock

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.